Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)

Exclusion Criteria

• •requires salvage intervention as defined by the ACC/AHA guidelines 10 as being ongoing cardiopulmonary resuscitation on the way to the operating room;
• •has current cardiogenic shock, acute left ventricular rupture, acute septal rupture or acute papillary muscle rupture;
• •has any active bacterial or other infection which is clinically significant, in the opinion of the Investigator (e.g. evaluate the evidence based on WBC, temperature, cultures etc. as appropriate for the patient);
• •has a known or suspected hereditary complement deficiency;
• •has participated in any other investigational drug study or was exposed to an investigational agent or device within 30 days of randomization;
• •is receiving, or is planning to receive, any other investigational drug or device, or will participate in any other research study within 30 days of randomization;
• •is pregnant or breast-feeding.